The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion ...
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...
Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...
A fatty liver is the most common. Dr Sudeep Khanna, senior consultant, gastroenterology, Indraprastha Apollo Hospitals, ...
The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...
The USA animal model market has reached a significant milestone, attaining an estimated valuation of USD 976.1 million in ...
Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for ... to non-alcoholic steatohepatitis (NASH) which includes hepatocellular injury, ...
When a company registers itself for the first time at the stock exchange to raise funds through shares, it enters the primary market. This is called an Initial Public Offering (IPO), after which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback